April 3rd 2024
In an interview with Targeted Oncology, Yanghee Woo, MD, discussed some factors to consider when choosing between CROSS and FLOT for gastreoesophageal junction adenocarcinoma treatment.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pembrolizumab Granted Priority Review by the FDA for Advanced Gastric Cancer
May 25th 2017Pembrolizumab (Keytruda) has been granted a priority review by the FDA for the treatment of patients who have undergone at least 2 courses of chemotherapy for recurrent or advanced gastric or gastroesophageal junction adenocarcinoma.
Read More
Ramucirumab Demonstrates Survival Benefit in Gastric/GEJ Cancers, Regardless of Age
January 23rd 2017In an analysis of 2 randomized trials,patients with advanced gastric or gastroesophageal juncture cancer derived a survival benefit from treatment with the monoclonal antibody ramucirumab, regardless of their age.<br />
Read More
Survival Doubled With Trastuzumab Beyond Progression in HER2+ Gastric Cancers
January 23rd 2017Continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.
Read More
Interim Results for Gastric Cancer Treatment With Ramucirumab Plus Pembrolizumab
January 21st 2017Ian Chau, MD, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.
Watch
Study Results Show Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer
January 20th 2017According to findings from the phase III ONO-4538-12 trial, treatment with nivolumab (Opdivo) reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction (GEJ) cancer following second or later-line chemotherapy.
Read More
The Impact of Age, Comorbidity on Postoperative Outcomes in Esophageal and Gastric Cancer
January 20th 2017Christophe Mariette, MD, PhD, surgical oncologist and professor of surgery, University Hospital of Lille in France, discusses a nationwide study investigating the impact of age and comorbidities on postoperative mortality after esophageal and gastric cancer surgery.
Watch
Expert Panel Provides Guidelines for HER2 Testing for GEA
November 19th 2016An expert panel, consisting of the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology issued comprehensive, evidence-based guidelines for clinicians and pathologists regarding the testing of HER2 status for patients with gastroesophageal adenocarcinoma.
Read More
Nivolumab Improves Survival in Advanced Gastric Cancer
November 11th 2016The PD-1 inhibitor nivolumab extended overall survival versus placebo for patients who were refractory or intolerant to standard therapy with unresectable, advanced, or recurrent gastric cancer, according to topline data from the phase III ONO-4538-12 trial.
Read More
Ilson Explains Evolving Role of PD-1 Inhibitors, HER2 Combinations in Gastric Cancer
September 27th 2016Newer agents, including immunotherapies and HER2 and VEGF-targeted therapies, are being investigated in gastric cancer, but the jury is still out on if these therapies will be beneficial, said David H. Ilson, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center.<br />
Read More
Expert Discusses New Targets, Developments on the Horizon in Gastric Cancer
September 27th 2016As gastric cancers continue to be classified into different subtypes, oncologists will now have the opportunity to improve treatment by determining which targeted agents are appropriate for which subtypes, said Howard S. Hochster, MD.<br />
Read More
JAVELIN Trial Design and Safety Results in Gastric Cancer
July 20th 2016Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, gives an overview of the JAVELIN trial in gastric cancer. He also discusses the safety profile of avelumab.
Watch
IMAB362 Plus Standard Chemo Results in Extended Overall Survival in Advanced Gastric Cancer
July 18th 2016IMAB362, a novel chimeric IgG1 backbone antibody highly specific for CLDN18.2, extended median overall survival by 4.8 months when added to standard chemotherapy in patients with advanced gastric cancer.
Read More
New Immunotherapy Agent Reduces Disease Progression Risk in Gastric Cancers
June 15th 2016Findings for the new immunotherapy agent targeting claudin18.2 (CLDN18.2) presented at the 2016 ASCO Annual Meeting raised the possibility of a new therapeutic agent in a tumor type with relatively few current options. When added to standard chemotherapy, the treatment reduced the risk of death or disease progression by approximately 50% for patients with CLDN18.2-positive advanced gastric cancers.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More
Selective FGFR Inhibitor Shows Promise in Gastric and Breast Cancers
June 4th 2016Gastric cancers with high-level clonal FGFR2 gene amplification responded to AZD4547, a selective FGFR inhibitor, in a phase II open label trial of previously treated, advanced FGFR amplified cancer. Yet tumors with multiple FGFR1 genes, low level or subclonal amplification of FGFR2 did not respond similarly to the drug.
Read More
Pessimism Surrounds VEGF Inhibitors in Advanced Gastric Cancer
May 26th 2016When a recent trial found that apatinib, an experimental VEGFR inhibitor, met its clinical endpoint and showed efficacy as a third-line therapy in treating advanced refractory stomach cancer, one might have expected at least two cheers. After all, gastric cancer is the third most fatal form of the disease globally, and there is currently no standard third-line treatment for advanced patients.
Read More